Overview

Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis

Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal